<< Proposed subsidies to expand coverage may miss some families | SoftScan clinical results from a breast cancer treatment monitoring study to be presented at IEEE International Conference >>
Read in | English | Bahasa

Alzheimer’s disease researcher joins UBC's European Scientific Advisory Board

Published on September 5, 2009 at 4:53 AM · No Comments

Leading Alzheimer’s Disease Researcher Will Support UBC’s Continuing Efforts to Improve Data Quality in CNS Clinical Trials

Key points:

  • UBC continues to maintain its scientific leadership in the field through its participation in the 2009 International Conference on Alzheimer's Disease (ICAD 2009) in Vienna, Austria.
  • United BioSource Corporation (UBC) announces during ICAD 2009 the addition of Professor Winblad to its European Scientific Advisory Board for CNS Clinical Trials

United BioSource Corporation (UBC) announced this summer at ICAD 2009 that Bengt Winblad, MD, PhD has joined its European Scientific Advisory Board for CNS Clinical Trials. Professor Winblad is one of the world’s leading Alzheimer’s disease researchers and currently serves as Professor of Geriatric Medicine and Chief Physician at the Karolinska University Hospital, Huddinge, and the Karolinska Institute in Stockholm, Sweden.

Prof. Winblad will work with UBC and its European Scientific Advisory Board to support their ongoing efforts to develop new approaches to ensure data quality in CNS clinical trials. Since its inception in 2008, UBC’s European Scientific Advisory board has contributed to new research regarding the methodological challenges in CNS research. Professor Winblad’s experience in Alzheimer’s disease gives the board an opportunity to continue its work of improving outcome measurement by addressing such key challenges as increasing placebo response rates and cultural variance associated with large, multi-national trials.

“A unified approach to enhancing methodology and exploring how we can improve the quality of data collected in clinical trials will help ensure that we are effectively investigating new treatments and expanding the options available to patients and their families suffering from Alzheimer’s disease,” said Prof. Winblad.

In addition to serving as the director of Karolinska Institute of Aging Research Center (ARC), KASPAC (Karolinska Institute Sumitomo Pharmaceutical Alzheimer Center) and the Swedish Brain Power Center of Excellence, Prof. Winblad is presently involved in an array of research activities and he serves as a reviewer of research centers in Europe and the United States. His research interests include epidemiology of dementias, the clinical evaluation and treatment of dementia conditions, especially Alzheimer’s disease, and the molecular genetics, pathology, and biochemistry of dementias. Prof. Winblad has more than 700 original publications in gerontology, geriatrics and dementia research.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading